Combined targeting of pathways regulating synaptic formation and autophagy attenuates Alzheimer’s disease pathology in mice

All drug trials completed to date have fallen short of meeting the clinical endpoint of significantly slowing cognitive decline in Alzheimer’s disease (AD) patients. In this study, we repurposed two FDA-approved drugs, Fasudil and Lonafarnib, targeting synaptic formation (i.e., Wnt signaling) and ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjorkli, Christiana, Hemler, Mary, Julian, Joshua B., Sandvig, Axel, Sandvig, Ioanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426773/
https://www.ncbi.nlm.nih.gov/pubmed/36052130
http://dx.doi.org/10.3389/fphar.2022.913971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426773/
https://www.ncbi.nlm.nih.gov/pubmed/36052130
http://dx.doi.org/10.3389/fphar.2022.913971

Ejemplares similares